Planta Med 2012; 78(1): 12-17
DOI: 10.1055/s-0031-1280219
Biological and Pharmacological Activity
Original Papers
© Georg Thieme Verlag KG Stuttgart · New York

ZYM-201 Sodium Succinate Ameliorates Streptozotocin-Induced Hyperlipidemic Conditions

Jongwon Choi1 [*] , Mi-Yeon Kim2 [*] , Bae Cheon Cha3 , Eun Sook Yoo4 , Keejung Yoon5 , Jaehwi Lee6 , Ho Sik Rho7 , Sun Young Kim8 , Jae Youl Cho5
  • 1College of Pharmacy, Kyungsung University, Busan, Korea
  • 2School of Systems Biological Science, Soongsil University, Seoul, Korea
  • 3College of Health Sciences, Sangji University, Wonju, Korea
  • 4College of Medicine, Cheju National University, Jeju, Korea
  • 5Department of Genetic Engineering, Sungkyunkwan University, Suwon, Korea
  • 6College of Pharmacy, Chung-Ang University, Seoul, Korea
  • 7Medical Beauty Research Institute, AmorePacific R & D Center, Yongin, Korea
  • 8Hongcheon Institute of Medicinal Herb, Hongcheon, Korea
Further Information

Publication History

received February 8, 2011 revised August 4, 2011

accepted August 16, 2011

Publication Date:
16 September 2011 (eFirst)


ZYM-201 is a methyl ester of a novel triterpenoid glycoside. It is isolated from Sanguisorba officinalis, a widely used medicinal plant in Korea, China, and Japan, that is prescribed for various diseases such as diarrhea, chronic intestinal infections, duodenal ulcers, and bleeding. In this study, the antihyperlipidemic effect of the salt form (sodium succinate) of ZYM-201 was examined using streptozotocin (STZ)-treated hyperglycemic rats. Oral administration of ZYM-201 sodium succinate (3 to 10 mg/kg) resulted in recovery of the increased serum levels of triglyceride (TG) and total cholesterol (TC) back to normal levels. Elevated levels of serum lipoproteins, such as high-density lipoprotein (HDL), low-density lipoprotein (LDL), and very low-density lipoprotein (VLDL), were also significantly restored by this compound without altering 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase activity. Finally, ZYM-201 sodium succinate displayed antioxidative properties, including suppression of lipid peroxide and hydroxyl radical generation and upregulation of superoxide dismutase (SOD) activity. Therefore, our data strongly suggest that ZYM-201 sodium succinate can be used as a remedy for the treatment of diabetes-derived hyperlipidemic disorders such as atherosclerosis and vascular diseases.